CA2307000A1 - Vaccins veterinaires - Google Patents

Vaccins veterinaires Download PDF

Info

Publication number
CA2307000A1
CA2307000A1 CA002307000A CA2307000A CA2307000A1 CA 2307000 A1 CA2307000 A1 CA 2307000A1 CA 002307000 A CA002307000 A CA 002307000A CA 2307000 A CA2307000 A CA 2307000A CA 2307000 A1 CA2307000 A1 CA 2307000A1
Authority
CA
Canada
Prior art keywords
clostridium
vaccine composition
vaccine
antigens
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002307000A
Other languages
English (en)
Other versions
CA2307000C (fr
Inventor
Richard Buchta
Christopher Leigh Schwartzkoff
Philip Ralph Lehrbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9722035.4A external-priority patent/GB9722035D0/en
Application filed by Individual filed Critical Individual
Publication of CA2307000A1 publication Critical patent/CA2307000A1/fr
Application granted granted Critical
Publication of CA2307000C publication Critical patent/CA2307000C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des vaccins vétérinaires qui sont destinés à la prévention de maladies clostridiales affectant les moutons (et agneaux) et qui assurent une immunité efficace pendant au moins un an après une seule injection ou dose.
CA2307000A 1997-10-17 1998-10-16 Vaccins veterinaires Expired - Lifetime CA2307000C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9722035.4 1997-10-17
GBGB9722035.4A GB9722035D0 (en) 1997-10-17 1997-10-17 Veterinary vaccines
PCT/AU1998/000865 WO1999020305A1 (fr) 1997-10-17 1998-10-16 Vaccins veterinaires

Publications (2)

Publication Number Publication Date
CA2307000A1 true CA2307000A1 (fr) 1999-04-29
CA2307000C CA2307000C (fr) 2011-01-04

Family

ID=25641911

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2307000A Expired - Lifetime CA2307000C (fr) 1997-10-17 1998-10-16 Vaccins veterinaires

Country Status (5)

Country Link
EP (1) EP1023083A4 (fr)
AU (1) AU753804B2 (fr)
CA (1) CA2307000C (fr)
NZ (1) NZ503636A (fr)
WO (1) WO1999020305A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824279B1 (fr) * 2001-05-04 2004-05-28 Seppic Sa Emulsion e/h concentree
FR2824269B1 (fr) * 2001-09-03 2012-03-02 Seppic Sa Composition adjuvante constituee de 1% a 15% de tensioactifs a hlb global compris entre 5 et 8 et de 85% a 99% de corps gras
NZ569627A (en) 2005-12-15 2012-01-12 Hancroft Pty Ltd The use of virginiamycin for preventing reduced feed intake and treating laminitis, fermentative acidosis, equine grass sickness and pulpy kidney
FR2903602B1 (fr) * 2006-07-12 2012-10-26 Seppic Sa Formulation injectable a liberation prolongee de principes actifs, procede pour sa preparation
FR2922767B1 (fr) 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
CN106177935A (zh) * 2016-08-19 2016-12-07 齐鲁动物保健品有限公司 一种反刍动物梭菌病四联灭活疫苗及其制备方法
GB201718251D0 (en) * 2017-11-03 2017-12-20 Univ Sydney Vaccine Compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1128325A (en) 1964-11-11 1968-09-25 Wellcome Found Improvements in water-in-oil emulsion vaccines
US3843451A (en) * 1970-08-20 1974-10-22 Burroughs Wellcome Co Microorganism production
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2717694B1 (fr) * 1994-03-22 1996-05-03 Seppic Sa Une composition comprenant un plasmide recombinant et ses utilisations comme vaccin et médicament.
US5814321A (en) * 1995-11-30 1998-09-29 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Oil adjuvant vaccine and method for preparing same
GB9626865D0 (en) 1996-12-24 1997-02-12 Cyanamid Websters Pty Limited Veterinary vaccines

Also Published As

Publication number Publication date
AU9616198A (en) 1999-05-10
NZ503636A (en) 2002-05-31
WO1999020305A8 (fr) 1999-07-08
EP1023083A1 (fr) 2000-08-02
WO1999020305A1 (fr) 1999-04-29
EP1023083A4 (fr) 2006-06-14
CA2307000C (fr) 2011-01-04
AU753804B2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
AU6210094A (en) Water-in-oil fluid vaccinal emulsions containing a metabolizable oil
NO965590D0 (no) Polynukleotidvaksine for papillomavirus
CA2307000A1 (fr) Vaccins veterinaires
CA2302554A1 (fr) Emulsions huile-dans-l'eau contenant des saponines
DK0764029T3 (da) Proteinadjuvanser
WO2000050006A3 (fr) Microemulsions a macromolecules et microparticules adsorbees
AU4324996A (en) Novel cyclodextrin-derivatives and methods for the preparation thereof
KR840003028A (ko) 종양치료제의 오일상 조성물의 제조방법
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
WO2000015256A3 (fr) Emulsion immunostimulante
AU1013701A (en) Modified gp100 and uses thereof
AU2238597A (en) Iscom or iscom-matrix comprising a mucus targetting substance and optionally, an antigen
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
WO2008055069A3 (fr) Vaccin contre l'entérite nécrosante de la volaille, qui comprend un antigène d'alpha-toxine de clostridium perfringens muté et procédés de production du vaccin
ATE249841T1 (de) Immunogene zubereitungen
DK0692974T4 (da) Multikomponent clostridiumvacciner hvor saponin anvendes som adjuvans
WO1999002132A3 (fr) Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn
AR008982A1 (es) Procedimiento para la preparacion de un material antigenico, soluble o no soluble en soluciones acuosas o exogeno, que comprende polisacaridos y/o glicopeptidos (asmp, anmp o aemp), dicho material antigenico, y su uso, vacuna y solucion inyectable a base del material antigenico, metodo que lo emplea
GB914894A (en) Injectable pharmaceutical media
AU1991097A (en) Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-linked treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
DE69332652T2 (de) Verbesserungen in bezug auf die herstellung von malariaimpstoffen
ATE258783T1 (de) Therapeutische und kosmetische mittel, ihre verwendung und herstellungsverfahren
WO2002040515A3 (fr) Toxine exoenzyme d'aeromonas salmonicida, et utilisations associees
DK0804234T3 (da) Adjuvans til vacciner
US20020098204A1 (en) Veterinary vaccines

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20181016